典型国家和地区罕见病用药保障模式比较及启示

李乐乐; 何晓彤; 陈湘妤; 李怡璇

doi:10.19546/j.issn.1674-3830.2022.11.005

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (11) : 29-34. DOI: 10.19546/j.issn.1674-3830.2022.11.005

专题分析

典型国家和地区罕见病用药保障模式比较及启示

李乐乐, 何晓彤, 陈湘妤, 李怡璇

作者信息 +

Comparison of Drug Security Models of Rare Diseases in Typical Countries and Regions and Its Enlightenment to China

Author information +

文章历史 +

摘要

健康是促进人类社会全面发展的必要条件,作为重点特殊人群,罕见病患者的用药保障不仅是一个医学问题,更是社会、经济和人权问题,构建符合中国国情的罕见病用药保障体系是实现全民健康的重要保障。本文通过对比典型国家和地区的罕见病用药保障模式,从法律法规、筹资方式、支付方式、管理机构和社会支持五个维度对典型模式进行梳理,为完善我国罕见病用药保障体系提出对策建议。

Abstract

Health plays an indispensable role in promoting all-round development for human beings. Medication security for patients with rare diseases, one of the special groups, is not only a medical issue, but also a social, economic, human rights issue. The construction of a healthcare security system for rare diseases in China is an inevitable step to achieve universal health. In this paper, we compare the rare disease drug security systems in typical countries, regions from aspects of laws, regulations, financing methods, payment methods, management organization, social support, put forward suggestions for improving the drug security system of rare diseases in China

导出引用

李乐乐, 何晓彤, 陈湘妤, 李怡璇. 典型国家和地区罕见病用药保障模式比较及启示[J]. 中国医疗保险. 2022, 0(11): 29-34 https://doi.org/10.19546/j.issn.1674-3830.2022.11.005

Comparison of Drug Security Models of Rare Diseases in Typical Countries and Regions and Its Enlightenment to China[J]. China Health Insurance. 2022, 0(11): 29-34 https://doi.org/10.19546/j.issn.1674-3830.2022.11.005

中图分类号： F840.684 C913.11

参考文献

[1] 张阳,杜建,张抒扬.罕见病的全球资助格局初探[J].国际药学研究杂志,2019,46( 9):710-715.
[2] 张晓星,周婷婷,潘杰. 国内外罕用药保障模式的评述[J].医疗保障, 2020,13(11):18-23.
[3] 唐彦,张学杰,刘鑫,等.国内外罕用药保障体系对比研究及其启示[J].中国药学杂志 2020,55(11):955-960.
[4] 王雪,赵聪,许淑红,等.我国罕用药可及性现状分析[J].中国临床药理学杂志2021, 37(8):1026-1032.
[5] Thamer M B N,Semansky R. A cross-national comparison of orphan drug policies: Implications for the US Orphan Drug Act[J].Journal of health policy and law,1998,23: 265-29.
[6] 易八贤,王广平,姬海红,等.美国孤儿药法案30年历程与我国新药创新制度体系完善[J]. 中国新药杂志2014,23(10):1107-1114.
[7] 张奇林,宋心璐.美国罕用药市场的激励机制及其启示[J].中国卫生政策研究 2016, 9(2): 36-44.
[8] Chan Adrienne Y.L. et al. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis[J]. Value in Health, 2020, 23(prepublish) : 1580-1591.
[9] Jyoti Tiwari.Navigating through orphan medicinal product regulations in EU and US Similarities and differences[J]. Regulatory Toxicology and Pharmacology, 2015, 71(1) : 63-67.
[10] Fan Minet al. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018[J]. Orphanet Journal of Rare Diseases, 2022, 17(1) : 3-3.
[11] Uchida K.Orphan drugs in Japan[J].Drug information journal,1996,30(1): 171-175.
[12] DING Z C,WEI G,DING J X.Orphan drug regime in Japan and its enlightenment to China based on evaluation of orphan drugs access in Japan[J]. China Pharmaceutical University(中国药科大学学报) ,2014,45( 1) : 118-124.
[13] XIN X X,GUAN X D,SHI L W.International comparative analysis and enlightenment of orphan drug incentive policies[J]. China J New Drug(中国新药杂志) ,2015(6): 605-609.
[14] Scott DL,Alder S,Usui E,et al.Orphan drug programs/policies in Australia,Japan,and Canada[J].Drug Inf J,2001,35(1): 11
[15] Nakamura and Takeda and Iwasaki. Identification of approval conditions for orphan drugs for neurological disorders by the Japanese regulatory agency[J]. Expert Opinion on Orphan Drugs, 2018, 6(7) : 441-447.
[16] Michel M, Toumi M.Access to orphan drugs in Europe: current and future issues. Expert Reviews Pharmacoeconomics Outcomes Research. 2012;12(1):23—9.
[17] Denis A, Mergaert L, Fostier C, et al.Issues surrounding orphan disease and orphan drug policies in Europe[J]. Applied health economics and health policy. 2010;8(5):343-50
[18] Aagaard L, Kristensen K.Access to cross-border health care services for patients with rare diseases in the European Union[J]. Orphan Drugs: research and reviews. 2014:39—45.
[19] Blankart A, Rudolf C, Stargardt T, et al.Availability of and access to orphan drugs[J]. Pharmacoeconomics. 2011;29(1):63—82.
[20] Trama A, Pierannunzio D, Loizzo A, et al.Availability of medicines for rare diseases in EU countries[J]. Pharmaceuticals Policy and Law 2009;11(1):101—109.
[21] V. Vanhoorneet al. Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases[J]. Orphanet Journal of Rare Diseases, 2019, 14(1) : 1-9.
[22] 台湾卫生福利事务主管部门“食品药物管理署”: 《罕见疾病药物处方集(2015年版)》[Z],2015.
[23] 肖建华,王超群.罕见病防治和保障的支持体系: 台湾的经验与启示[J]. 社会保障研究2018,2:92-105.
[24] 林禹鸿,吴晓明.台湾罕用药法律制度给我们的启示[J]. 法治研究,2012, 6 : 87-91.
[25] 马正,高嘉敏,赵艺皓,等. 罕见病政策国际经验及对我国的启示[J].中国卫生政策研究 2018, 11(11):61-67.